Ribavirin treatment in murine autoimmune disease

Lynell W. Klassen, Gary W. Williams, James L. Reinertsen, N. Lynn Gerber, Alfred D. Steinberg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

NZB/W F, female mice were treated from 20 weeks of age with ribavirin (a broad spectrum antiviral drug), cyclophosphamide, or saline. Treatment with ribavirin (250 mg/kg twice weekly) prolonged survival from 9.8 to 18.5 months, reduced anti‐DNA antibodies, and prevented proteinuria. Ability of ribavirin to prolong survival was dose related when given on a twice weekly schedule. However, daily ribavirin (25 mg/kg/day) was as effective as higher intermittent doses. Optimal ribavirin therapy was equal to cyclophosphamide treatment with regard to prolongation of survival. Ribavirin treatment did not significantly alter the body weight, hematocrit, WBC count, serum immunoglobulins, or Coombs reactivity. No alterations in either cellular or humoral immune responses were noted in NZB/W F, or BALB/c mice treated for prolonged periods with ribavirin. The impressive therapeutic response to a broad spectrum antiviral agent seen in mice already manifesting immune complex nephritis provides a new therapeutic approach to the treatment of autoimmunity.

Original languageEnglish (US)
Pages (from-to)145-154
Number of pages10
JournalArthritis & Rheumatism
Volume22
Issue number2
DOIs
StatePublished - Feb 1979

Fingerprint

Ribavirin
Autoimmune Diseases
Cyclophosphamide
Antiviral Agents
Nephritis
Humoral Immunity
Antigen-Antibody Complex
Autoimmunity
Hematocrit
Proteinuria
Cellular Immunity
Immunoglobulins
Appointments and Schedules
Therapeutics
Body Weight
Antibodies
Serum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Klassen, L. W., Williams, G. W., Reinertsen, J. L., Gerber, N. L., & Steinberg, A. D. (1979). Ribavirin treatment in murine autoimmune disease. Arthritis & Rheumatism, 22(2), 145-154. https://doi.org/10.1002/art.1780220207

Ribavirin treatment in murine autoimmune disease. / Klassen, Lynell W.; Williams, Gary W.; Reinertsen, James L.; Gerber, N. Lynn; Steinberg, Alfred D.

In: Arthritis & Rheumatism, Vol. 22, No. 2, 02.1979, p. 145-154.

Research output: Contribution to journalArticle

Klassen, LW, Williams, GW, Reinertsen, JL, Gerber, NL & Steinberg, AD 1979, 'Ribavirin treatment in murine autoimmune disease', Arthritis & Rheumatism, vol. 22, no. 2, pp. 145-154. https://doi.org/10.1002/art.1780220207
Klassen LW, Williams GW, Reinertsen JL, Gerber NL, Steinberg AD. Ribavirin treatment in murine autoimmune disease. Arthritis & Rheumatism. 1979 Feb;22(2):145-154. https://doi.org/10.1002/art.1780220207
Klassen, Lynell W. ; Williams, Gary W. ; Reinertsen, James L. ; Gerber, N. Lynn ; Steinberg, Alfred D. / Ribavirin treatment in murine autoimmune disease. In: Arthritis & Rheumatism. 1979 ; Vol. 22, No. 2. pp. 145-154.
@article{b6ba8098de8c428ba54d7eb7d3570a48,
title = "Ribavirin treatment in murine autoimmune disease",
abstract = "NZB/W F, female mice were treated from 20 weeks of age with ribavirin (a broad spectrum antiviral drug), cyclophosphamide, or saline. Treatment with ribavirin (250 mg/kg twice weekly) prolonged survival from 9.8 to 18.5 months, reduced anti‐DNA antibodies, and prevented proteinuria. Ability of ribavirin to prolong survival was dose related when given on a twice weekly schedule. However, daily ribavirin (25 mg/kg/day) was as effective as higher intermittent doses. Optimal ribavirin therapy was equal to cyclophosphamide treatment with regard to prolongation of survival. Ribavirin treatment did not significantly alter the body weight, hematocrit, WBC count, serum immunoglobulins, or Coombs reactivity. No alterations in either cellular or humoral immune responses were noted in NZB/W F, or BALB/c mice treated for prolonged periods with ribavirin. The impressive therapeutic response to a broad spectrum antiviral agent seen in mice already manifesting immune complex nephritis provides a new therapeutic approach to the treatment of autoimmunity.",
author = "Klassen, {Lynell W.} and Williams, {Gary W.} and Reinertsen, {James L.} and Gerber, {N. Lynn} and Steinberg, {Alfred D.}",
year = "1979",
month = "2",
doi = "10.1002/art.1780220207",
language = "English (US)",
volume = "22",
pages = "145--154",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Ribavirin treatment in murine autoimmune disease

AU - Klassen, Lynell W.

AU - Williams, Gary W.

AU - Reinertsen, James L.

AU - Gerber, N. Lynn

AU - Steinberg, Alfred D.

PY - 1979/2

Y1 - 1979/2

N2 - NZB/W F, female mice were treated from 20 weeks of age with ribavirin (a broad spectrum antiviral drug), cyclophosphamide, or saline. Treatment with ribavirin (250 mg/kg twice weekly) prolonged survival from 9.8 to 18.5 months, reduced anti‐DNA antibodies, and prevented proteinuria. Ability of ribavirin to prolong survival was dose related when given on a twice weekly schedule. However, daily ribavirin (25 mg/kg/day) was as effective as higher intermittent doses. Optimal ribavirin therapy was equal to cyclophosphamide treatment with regard to prolongation of survival. Ribavirin treatment did not significantly alter the body weight, hematocrit, WBC count, serum immunoglobulins, or Coombs reactivity. No alterations in either cellular or humoral immune responses were noted in NZB/W F, or BALB/c mice treated for prolonged periods with ribavirin. The impressive therapeutic response to a broad spectrum antiviral agent seen in mice already manifesting immune complex nephritis provides a new therapeutic approach to the treatment of autoimmunity.

AB - NZB/W F, female mice were treated from 20 weeks of age with ribavirin (a broad spectrum antiviral drug), cyclophosphamide, or saline. Treatment with ribavirin (250 mg/kg twice weekly) prolonged survival from 9.8 to 18.5 months, reduced anti‐DNA antibodies, and prevented proteinuria. Ability of ribavirin to prolong survival was dose related when given on a twice weekly schedule. However, daily ribavirin (25 mg/kg/day) was as effective as higher intermittent doses. Optimal ribavirin therapy was equal to cyclophosphamide treatment with regard to prolongation of survival. Ribavirin treatment did not significantly alter the body weight, hematocrit, WBC count, serum immunoglobulins, or Coombs reactivity. No alterations in either cellular or humoral immune responses were noted in NZB/W F, or BALB/c mice treated for prolonged periods with ribavirin. The impressive therapeutic response to a broad spectrum antiviral agent seen in mice already manifesting immune complex nephritis provides a new therapeutic approach to the treatment of autoimmunity.

UR - http://www.scopus.com/inward/record.url?scp=0018772543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018772543&partnerID=8YFLogxK

U2 - 10.1002/art.1780220207

DO - 10.1002/art.1780220207

M3 - Article

C2 - 33680

AN - SCOPUS:0018772543

VL - 22

SP - 145

EP - 154

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -